Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 3/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10583212 | 0.98 | CYP2C19 (0.46) | CYP2C19MMEP2RX7USP2ALDH1A1 | |
| SCHEMBL5722357 | 0.98 | CYP2C19 (0.44) | CYP2C19MMEP2RX7 | |
| SCHEMBL17234220 | 0.94 | CYP2C19 (0.39) | CYP2C19MME | |
| SCHEMBL17234215 | 0.90 | CYP2C19 (0.33) | CYP2C19ALDH1A1TSHR | |
| SCHEMBL6847900 | 0.87 | P2RX7 (0.42) | CYP2C19MMEP2RX7ALDH1A1LMNA | |
| SCHEMBL1127363 | 0.78 | CYP2C19 (0.47) | CYP2C19MMEP2RX7USP2ALDH1A1 | |
| SCHEMBL9543283 | 0.77 | CYP2C19 (0.50) | CYP2C19MMEALDH1A1LMNATSHR | |
| SCHEMBL30879561 | 0.76 | CYP2C19 (0.58) | CYP2C19MMEUSP2ALDH1A1LMNA | |
| SCHEMBL6307086 | 0.76 | CYP2C19 (0.48) | CYP2C19MMELMNATBXAS1 | |
| SCHEMBL6400273 | 0.75 | FAAH (0.40) | P2RX7ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0775692-B1 | GUANIDINOMETHYL CYCLOHEXANE CARBOXYLIC ESTER DERIVATIVE | TEIKOKU CHEM IND CO LTD (JP) | 2000-12-06 | — | — | EP | claimed |
| EP-0775692-A1 | GUANIDINOMETHYL CYCLOHEXANE CARBOXYLIC ESTER DERIVATIVE | TEIKOKU CHEMICAL INDUSTRY CO., LTD. (JP) | 1997-05-28 | — | — | EP | claimed |
| EP-2420500-A1 | PYRIDINE THIO DERIVATIVE, AND PHARMACEUTICAL COMPOSITION WHICH CONTAINS SAME AND HAS ANTI-HELICOBACTER PYLORI ACTION | aRigen Pharmaceuticals, Inc. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120041030-A1 | PYRIDINE THIO DERIVATIVE, AND PHARMACEUTICAL COMPOSITION WHICH CONTAINS SAME AND HAS ANTI-HELICOBACTER PYLORI ACTION | LINK GENOMICS, INC. (JP) | 2012-02-16 | — | — | US | disclosed |
| EP-1449828-B1 | Guanidinomethyl cyclohexane carboxylic acid ester derivatives | NAGASE CHEMTEX CORP (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-6960681-B2 | Guanidinomethyl cyclohexane carboxylic acid ester derivatives | NAGASE CHEMTEX CORPORATION (JP) | 2005-11-01 | — | — | US | disclosed |
| US-20050075402-A1 | Guanidinomethyl cyclohexane carboxylic acid ester derivatives | TEIKOKU CHEMICAL INDUSTRIES CO., LTD. | 2005-04-07 | — | — | US | disclosed |
| US-6831190-B1 | Acts effectively in stomach, the antibacterial activity becomes weak as the compounds moves from duodenum to small intestines; do not have activity against esylhiacori, staphylococcus aureus, methacycline resistant bacterium | TEIKOKU CHEMICAL INDUSTRIES CO., LTD. (JP) | 2004-12-14 | — | — | US | disclosed |
| EP-1449828-A2 | Guanidinomethyl cyclohexane carboxylic acid ester derivatives | Nagase ChemteX Corporation (JP) | 2004-08-25 | — | — | EP | disclosed |
| EP-0989112-B1 | Intermediates for the preparation of guanidinomethyl cyclohexane carboxylic acid ester derivatives | NAGASE CHEMTEX CORP (JP) | 2004-04-14 | — | — | EP | disclosed |
| JP-2002128670-A | MEDICINAL COMPOSITION FOR TABLET | NAGASE IYAKUHIN KK | 2002-05-09 | — | — | JP | disclosed |
| US-6284791-B1 | USEFUL AS AN ANTI-MICROBIAL AGAINST HELICOBACTER PYLORI | TEIKOKU CHEMICAL INDUSTRIES CO., LTD. (JP) | 2001-09-04 | — | — | US | disclosed |
| EP-0775692-B1 | GUANIDINOMETHYL CYCLOHEXANE CARBOXYLIC ESTER DERIVATIVE | TEIKOKU CHEM IND CO LTD (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-0989112-A2 | Intermediates for the preparation of guanidinomethyl cyclohexane carboxylic acid ester derivatives | TEIKOKU CHEMICAL INDUSTRY CO., LTD. (JP) | 2000-03-29 | — | — | EP | disclosed |
| EP-0775692-A1 | GUANIDINOMETHYL CYCLOHEXANE CARBOXYLIC ESTER DERIVATIVE | TEIKOKU CHEMICAL INDUSTRY CO., LTD. (JP) | 1997-05-28 | — | — | EP | disclosed |
| EP-0193965-B1 | NOVEL GUANIDINOMETHYLCYCLOHEXANCARBOXYLIC ACID COMPOUNDS, PROCESSES FOR PREPARING THEM, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | KANEBO, LTD. (JP) | 1988-11-30 | — | — | EP | disclosed |
| US-4681895-A | Novel guanidinomethylcyclohexanecarboxylic acid compounds and anti-ulcer drug containing the same | KANEBO, LTD. (JP) | 1987-07-21 | — | — | US | disclosed |
| US-4681895-A | Novel guanidinomethylcyclohexanecarboxylic acid compounds and anti-ulcer drug containing the same | KANEBO, LTD. (JP) | 1987-07-21 | — | — | US | disclosed |
| EP-0193965-A2 | Novel guanidinomethylcyclohexancarboxylic acid compounds, processes for preparing them, and pharmaceutical compositions containing them | KANEBO, LTD. (JP) | 1986-09-10 | — | — | EP | disclosed |
| EP-0193965-A2 | Novel guanidinomethylcyclohexancarboxylic acid compounds, processes for preparing them, and pharmaceutical compositions containing them | KANEBO, LTD. (JP) | 1986-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041030-A1 | PYRIDINE THIO DERIVATIVE, AND PHARMACEUTICAL COMPOSITION WHICH CONTAINS SAME AND HAS ANTI-HELICOBACTER PYLORI ACTION | TPMT, TST, PTPN11 | CYP2C19 81/4885MME 4461/4885P2RX7 157/4885 |
| US-20050075402-A1 | Guanidinomethyl cyclohexane carboxylic acid ester derivatives | GCK, ADCY9, ADCY7 | CYP2C19 55/4885MME 3680/4885P2RX7 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.